- ISIN
- US09077D1000
- CUSIP
- 09077D100
- Sector
- Healthcare
- IPO Date
- Oct 29, 2021
Highlights
- Market Cap
- $12.03M
- Enterprise Value
- $13.95M
- EPS (TTM)
- -$1.02
- Total Revenue (TTM)
- $43.20M
- Gross Profit (TTM)
- $35.77M
- EBITDA (TTM)
- -$8.27M
- Year Range
- $0.55 - $1.19
- ROA (TTM)
- -44.72%
- ROE (TTM)
- -182.62%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BFRI Performance Chart
Biofrontera Inc. (BFRI) is up 80.7% since the beginning of the year. At $1 per share, BFRI is trading 13.4% below its 52-week high of $1.
Loading charts...
Returns By Period
Biofrontera Inc. (BFRI) has returned 80.70% so far this year and 54.93% over the past 12 months.
Biofrontera Inc.
- 1D
- 7.94%
- 1M
- -7.21%
- YTD
- 80.70%
- 6M
- 29.79%
- 1Y
- 54.93%
- 3Y*
- -52.45%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.68%
- YTD
- 11.16%
- 6M
- 11.10%
- 1Y
- 27.46%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
BFRI Monthly Returns History
Based on dividend-adjusted daily data since Oct 29, 2021, BFRI's average daily return is -0.11%, while the average monthly return is -3.93%.
Historically, 38% of months were positive and 63% were negative. The best month was Mar 2024 with a return of +83.8%, while the worst month was Jan 2022 at -54.9%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.
On a daily basis, BFRI closed higher 44% of trading days. The best single day was Nov 24, 2021 with a return of +98.5%, while the worst single day was Feb 2, 2024 at -31.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 63.21% | -2.01% | -11.25% | 33.50% | -17.96% | 16.25% | 80.70% | ||||||
| 2025 | 3.67% | -13.69% | -17.97% | -12.50% | -19.71% | 26.60% | 51.79% | -17.95% | 11.16% | 11.68% | -25.74% | -30.22% | -47.71% |
| 2024 | -51.99% | -37.02% | 83.84% | 19.48% | -44.02% | -12.82% | 33.62% | -9.16% | 22.02% | -7.52% | -26.83% | 21.11% | -60.65% |
| 2023 | -7.29% | -12.87% | -17.61% | -3.28% | -20.34% | 10.64% | 12.88% | -26.24% | 1.27% | -46.41% | -28.80% | -17.22% | -84.89% |
| 2022 | -54.92% | -12.98% | 12.88% | 11.11% | -22.43% | -35.19% | -23.12% | -18.88% | -9.48% | 2.86% | -2.78% | -12.70% | -87.81% |
| 2021 | 35.83% | 25.54% | 70.52% |
Benchmark Metrics
Biofrontera Inc. has an annualized alpha of -32.87%, beta of 1.01, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 01, 2021.
- This stock participated in 224.41% of S&P 500 Index downside but only -63.38% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -32.87%
- Beta
- 1.01
- R²
- 0.02
- Upside Capture
- -63.38%
- Downside Capture
- 224.41%
Return for Risk
Risk / Return Rank
BFRI ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Biofrontera Inc. (BFRI) and compare them to S&P 500 Index.
| BFRI | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.99 | 2.39 | -1.40 |
Sortino ratioReturn per unit of downside risk | 1.90 | 3.25 | -1.36 |
Omega ratioGain probability vs. loss probability | 1.24 | 1.43 | -0.19 |
Calmar ratioReturn relative to maximum drawdown | 1.58 | 3.11 | -1.53 |
Martin ratioReturn relative to average drawdown | 3.88 | 14.38 | -10.50 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Biofrontera Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Biofrontera Inc. was 99.79%, occurring on May 30, 2025. The portfolio has not yet recovered.
The current Biofrontera Inc. drawdown is 99.61%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.79%May 2025 | 3y 5mo | — | 4y 5moDec 2021 - now |
2021 bear market2021 | -46.20%Dec 2021 | 7d | 15d | 22dNov 2021 - Dec 2021 |
2021 bear market2021 | -43.99%Nov 2021 | 21d | 2d | 23dNov 2021 - Nov 2021 |
2021 pullback2021 | -4.81%Dec 2021 | 0s | 1d | 1dDec 2021 - Dec 2021 |
Drawdown Indicators
| BFRI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.79% | -56.78% | -43.01% |
Max Drawdown (1Y)Largest decline over 1 year | -50.86% | -9.10% | -41.76% |
Max Drawdown (3Y)Largest decline over 3 years | -95.59% | -18.90% | -76.69% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.61% | 0.00% | -99.61% |
Average DrawdownAverage peak-to-trough decline | -92.45% | -10.72% | -81.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.73% | 1.97% | +18.76% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Biofrontera Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Biofrontera Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for BFRI relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, BFRI has a P/S ratio of 0.3. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BFRI in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, BFRI has a P/B value of 2.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BFRI
Add Biofrontera Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BFRI